Company profile
GENELUX Corp
NASDAQ:GNLXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OLVIMULOGENE NANIVACIREPVEC | phase3 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01443260 | phase1_2 | completed | 2012-02-01 | 2014-09-01 | Genelux GmbH | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis |
| NCT05281471 | phase3 | recruiting | 2022-08-31 | 2026-12-01 | Genelux Corporation | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
| NCT06463665 | phase2 | recruiting | 2024-09-26 | 2027-02-01 | Genelux Corporation | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer |
| NCT02759588 | phase1_2 | completed | 2016-05-01 | 2021-12-31 | Genelux Corporation | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer |
| NCT01584284 | phase1 | completed | 2012-04-01 | 2015-06-01 | Genelux Corporation | Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer |
FDA applications (0)
No records yet.